GLC-001

GLC-001 is a small molecule therapeutic candidate being developed by Omic Analytics for the treatment of glaucoma. Currently in the lead optimization stage, the drug is designed to modulate the trabecular meshwork outflow pathway to enhance the drainage of aqueous humor and subsequently lower intraocular pressure. While the specific molecular target remains undisclosed, the program leverages Omic Analytics' AI-driven discovery platform to identify novel mechanisms for restoring conventional outflow, which is often impaired in glaucomatous eyes. By targeting the primary site of outflow resistance, GLC-001 aims to provide a more physiological approach to managing ocular hypertension compared to therapies that primarily reduce fluid production.